Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cefoxitin use review.

J M Lazor-Bajcar1

  • 1St. Michael's Hospital, Toronto, Ontario M5B 1W8.

The Canadian Journal of Hospital Pharmacy
|October 1, 1990
PubMed
Summary
This summary is machine-generated.

A drug utilization review found 42% of cefoxitin use was inappropriate, costing the hospital significantly. Optimizing cefoxitin prescribing could save an estimated $11,873 annually.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The development and implementation of a drug utilization review program.

The Canadian journal of hospital pharmacy·1988
See all related articles

Area of Science:

  • Pharmacology
  • Health Services Research

Background:

  • Increased cefoxitin utilization at The Mississauga Hospital prompted a Drug Utilization Review (DUR).
  • Previous data on cefoxitin prescribing patterns and associated costs were limited.

Purpose of the Study:

  • To analyze cefoxitin prescribing patterns and assess the appropriateness of its use.
  • To quantify the financial impact of inappropriate cefoxitin prescriptions.
  • To estimate potential cost savings through optimized cefoxitin utilization.

Main Methods:

  • Retrospective review of 100 cefoxitin therapy courses for 82 patients over four months.
  • Evaluation by a pharmacist and infectious disease specialist using predefined appropriateness criteria.
  • Analysis of prescribing departments, agent choice, and treatment/prophylaxis duration.

Related Experiment Videos

Main Results:

  • Surgery (45%), obstetrics/gynecology (31%), and medicine (24%) were primary prescribers.
  • 42% of cefoxitin courses were inappropriate, and 11% were questionable.
  • Inappropriate use accounted for 62% agent choice issues and 33% duration problems, representing 22% of total cefoxitin costs.

Conclusions:

  • Significant opportunities exist to improve cefoxitin prescribing quality and reduce healthcare expenditure.
  • Optimized cefoxitin use could lead to estimated annual savings of $11,873.
  • Concurrent DURs with pharmacist interventions proved cost-effective in improving cefoxitin utilization.